NI200900177A - 3 - imidazolil - indoles para el tratamiento de enfermedades proliferativas. - Google Patents

3 - imidazolil - indoles para el tratamiento de enfermedades proliferativas.

Info

Publication number
NI200900177A
NI200900177A NI200900177A NI200900177A NI200900177A NI 200900177 A NI200900177 A NI 200900177A NI 200900177 A NI200900177 A NI 200900177A NI 200900177 A NI200900177 A NI 200900177A NI 200900177 A NI200900177 A NI 200900177A
Authority
NI
Nicaragua
Prior art keywords
treatment
proliferative diseases
imidazolil
indoles
variants
Prior art date
Application number
NI200900177A
Other languages
English (en)
Inventor
Boettcher Andreas
Buschmann Nicole
Furet Pascal
Groell Jean-Marc
Kallen Jörg
Hergovich Lisztwan Joanna
Masuya Keiichi
Mayr Lorenz
Vaupel Andrea
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38328915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI200900177(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NI200900177A publication Critical patent/NI200900177A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a compuestos de 3 - heterociclil - indolilo capaces de inhibir la interacción entre p53, o variantes del mismo, y MDM2 y/o MDM4, o variantes de los mismos, respectivamente, teniendo estos compuestos la fórmula I: en donde R1, R2, R3, R4, RA, e Y son como se definen en la memoria descriptiva. Debido a su actividad, los compuestos son útiles en el tratamiento de diferentes trastornos y enfermedades mediadas por la actividad de MDM2 y/o MDM4, o variantes de los mismos, tales como enfermedades inflamatorias o proliferativas, o en la protección de las células.
NI200900177A 2007-03-29 2009-09-28 3 - imidazolil - indoles para el tratamiento de enfermedades proliferativas. NI200900177A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07105269 2007-03-29

Publications (1)

Publication Number Publication Date
NI200900177A true NI200900177A (es) 2010-09-09

Family

ID=38328915

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200900177A NI200900177A (es) 2007-03-29 2009-09-28 3 - imidazolil - indoles para el tratamiento de enfermedades proliferativas.

Country Status (27)

Country Link
US (1) US8053457B2 (es)
EP (1) EP2142535A2 (es)
JP (1) JP2010522723A (es)
KR (1) KR20090122403A (es)
CN (1) CN101679382A (es)
AR (1) AR065860A1 (es)
AU (1) AU2008234954B9 (es)
BR (1) BRPI0810082A2 (es)
CA (1) CA2682483A1 (es)
CL (1) CL2008000899A1 (es)
CR (1) CR11019A (es)
DO (1) DOP2009000229A (es)
EA (1) EA200901212A1 (es)
EC (1) ECSP099660A (es)
GT (1) GT200900256A (es)
IL (1) IL200862A0 (es)
MA (1) MA31260B1 (es)
MX (1) MX2009010413A (es)
NI (1) NI200900177A (es)
PA (1) PA8774001A1 (es)
PE (1) PE20081897A1 (es)
SM (1) SMP200900085B (es)
TN (1) TN2009000388A1 (es)
TW (1) TW200843746A (es)
UY (1) UY30987A1 (es)
WO (1) WO2008119741A2 (es)
ZA (1) ZA200906210B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2010172B1 (en) * 2006-04-07 2012-08-29 Janssen Pharmaceutica N.V. Indoles and benzoimidazoles as modulators of the histamine h4 receptor
AR070398A1 (es) * 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
US20100035862A1 (en) * 2008-06-25 2010-02-11 Abbott Laboratories Novel aza-cyclic indole-2-carboxamides and methods of use thereof
CA2742954C (en) 2008-11-07 2018-07-10 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
KR20110119641A (ko) * 2009-01-16 2011-11-02 다이이찌 산쿄 가부시키가이샤 프롤린 고리 구조를 갖는 이미다조티아졸 유도체
JP2012102017A (ja) * 2009-03-03 2012-05-31 Astellas Pharma Inc インドール化合物
EP2419408A4 (en) * 2009-04-16 2012-09-05 Msd Kk INDOLE SUBSTITUTED DERIVATIVE IN POSITION 3 BY ARYL OR HETEROARYLE
CA2780547C (en) 2009-11-12 2015-02-03 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
WO2011106650A2 (en) * 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
WO2012033525A2 (en) 2010-09-08 2012-03-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education P53-mdm2 antagonists
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
EA201390682A1 (ru) 2010-11-12 2014-01-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Спирооксиндольные антагонисты mdm2
US20120202794A1 (en) * 2011-01-24 2012-08-09 Pharmasset, Inc. Compounds
SI2684880T1 (en) 2011-03-10 2018-08-31 Daiichi Sankyo Company, Limited DERIVAT DISPIROPYROLIDINE
CN102702066A (zh) * 2011-03-28 2012-10-03 苏州百灵威超精细材料有限公司 一种用于合成抗癌和减肥药物中间体6-氯-5-氟吲哚的制备新方法
PL2691443T3 (pl) 2011-03-28 2021-08-30 Massachusetts Institute Of Technology Sprzężone lipomery i ich zastosowania
JP2014513699A (ja) 2011-05-11 2014-06-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
WO2012176123A1 (en) * 2011-06-22 2012-12-27 Novartis Ag 3 - imidazolyl- indoles for the treatment of proliferative diseases
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
JP2015502366A (ja) 2011-12-13 2015-01-22 バック インスティテュート フォー リサーチ オン エイジング 薬物療法を改善するための方法
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
AR094116A1 (es) 2012-12-20 2015-07-08 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de hdm2
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
US9993472B2 (en) 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
EP3708170A1 (en) 2014-05-05 2020-09-16 BioVentures, LLC Compositions and methods for inhibiting antiapoptotic bcl-2 proteins as anti-aging agents
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
WO2016001376A1 (en) 2014-07-03 2016-01-07 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
JP2017522388A (ja) 2014-07-22 2017-08-10 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 老化細胞を選択的に枯渇させるための組成物及び方法
WO2016101865A1 (en) 2014-12-26 2016-06-30 Dow Global Technologies Llc Organic compounds and electronic device comprising organic layer comprising organic compounds
ES2968789T3 (es) 2015-02-20 2024-05-14 Daiichi Sankyo Co Ltd Procedimiento combinado para el tratamiento del cáncer
JP6823587B2 (ja) 2015-04-13 2021-02-03 第一三共株式会社 Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法
CN108025084B (zh) * 2015-06-22 2024-08-09 拜耳医药股份有限公司 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc）
JOP20160198B1 (ar) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3359542B1 (en) 2015-10-09 2021-03-17 Boehringer Ingelheim International GmbH Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
CN109415336B (zh) 2016-04-06 2023-08-29 密执安大学评议会 Mdm2蛋白质降解剂
US10759808B2 (en) 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
CN109152933B (zh) 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
CN105906610B (zh) * 2016-05-24 2018-10-23 绍兴文理学院 一种3-（4-苯基-1h-咪唑-5-基）-1h-吲哚衍生物及其制备方法和应用
EP3272745B1 (en) * 2016-07-21 2019-06-26 Instytut Farmakologii Polskiej Akademii Nauk Imidazolyl-substituted indole derivatives binding 5-ht7 serotonin receptor and pharmaceutical compositions thereof
KR20190068544A (ko) 2016-10-17 2019-06-18 다이이찌 산쿄 가부시키가이샤 Mdm2 저해제와 dna 메틸트랜스페라아제 저해제의 병용 치료법
EP3544979B1 (en) 2016-11-28 2021-08-04 F. Hoffmann-La Roche AG Oxadiazolones as transient receptor potential channel inhibitors
EP3558388A1 (de) 2016-12-21 2019-10-30 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen
WO2018162607A1 (en) 2017-03-07 2018-09-13 F. Hoffmann-La Roche Ag Oxadiazole transient receptor potential channel inhibitors
AU2018248586A1 (en) 2017-04-05 2019-09-05 Boehringer Ingelheim International Gmbh Anticancer combination therapy
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
EP3630109A4 (en) * 2017-05-26 2021-03-17 Rutgers, the State University of New Jersey BACTERIAL DRAIN PUMP INHIBITORS
CA3088253A1 (en) 2018-01-22 2019-07-25 Bioventures, Llc Bcl-2 proteins degraders for cancer treatment
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
US12084423B2 (en) 2018-05-18 2024-09-10 Bioventures, Llc Piperlongumine analogues and uses thereof
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
CN113474340B (zh) * 2019-02-26 2024-07-23 勃林格殷格翰国际有限公司 作为ras抑制剂的新型异吲哚啉酮取代的吲哚和衍生物
KR20230124665A (ko) * 2020-12-22 2023-08-25 노파르티스 아게 Cgas 관련 병태의 치료에 유용한 인돌 유도체
US20220306609A1 (en) * 2021-03-23 2022-09-29 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19948417A1 (de) * 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
JP2002114780A (ja) * 2000-10-11 2002-04-16 Taisho Pharmaceut Co Ltd ４−（３−インドリル）イミダゾール誘導体
JP5248866B2 (ja) 2005-02-22 2013-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｄｍ２の小分子阻害剤およびその使用
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives

Also Published As

Publication number Publication date
SMAP200900085A (it) 2010-01-19
CR11019A (es) 2009-10-20
IL200862A0 (en) 2010-05-17
KR20090122403A (ko) 2009-11-27
JP2010522723A (ja) 2010-07-08
CL2008000899A1 (es) 2009-02-20
EP2142535A2 (en) 2010-01-13
WO2008119741A3 (en) 2008-12-04
DOP2009000229A (es) 2009-10-31
MX2009010413A (es) 2009-10-20
WO2008119741A2 (en) 2008-10-09
PA8774001A1 (es) 2008-11-19
US8053457B2 (en) 2011-11-08
UY30987A1 (es) 2008-10-31
CA2682483A1 (en) 2008-10-09
SMP200900085B (it) 2010-11-12
EA200901212A1 (ru) 2010-04-30
PE20081897A1 (es) 2009-02-09
TN2009000388A1 (en) 2010-12-31
MA31260B1 (fr) 2010-03-01
AR065860A1 (es) 2009-07-08
US20100125064A1 (en) 2010-05-20
ZA200906210B (en) 2010-05-26
ECSP099660A (es) 2009-10-30
AU2008234954A1 (en) 2008-10-09
BRPI0810082A2 (pt) 2014-10-21
AU2008234954B2 (en) 2011-10-27
CN101679382A (zh) 2010-03-24
GT200900256A (es) 2010-03-15
TW200843746A (en) 2008-11-16
AU2008234954B9 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
NI200900177A (es) 3 - imidazolil - indoles para el tratamiento de enfermedades proliferativas.
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
ECSP11011079A (es) Nuevos compuestos de hidroxiareno.
NI201000013A (es) Sulfonamidas como moduladores del trpm8
CU24414B1 (es) Lactamas n-(heteroarilo sustituido) fusionadas útiles en el tratamiento del crecimiento celular anormal
CL2012000583A1 (es) Compuestos derivados de quinazolinas sustituidas, inhibidores de los canales ionicos de potasio; composicion farmaceutica que los comprende; uso del compuesto para tratar o prevenir arritmias, controlar la frecuencia cardiaca, entre otras.
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
CU24087B1 (es) Compuestos de carbazol
UY29636A1 (es) 2,4-diamino-pirimidinas como inhibidores de aurora
CU20120099A7 (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
UY31072A1 (es) Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido
DOP2009000190A (es) Compuestos triciclicos y su uso como moduladores de receptor de glucocorticoides
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CO6331434A2 (es) Nuevos compuestos
ECSP11010867A (es) Compuestos novedosos de fenilamino-isonicotinamida
CU20140103A7 (es) Compuestos de cromano sustituidos como modulares del receptor sensible al calcio
UY31016A1 (es) Nuevos compuestos heterociclicos nitrogenados, su preparacion y su utilizacion como medicamentos antibacterianos
CR11759A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
PE20150707A1 (es) Inhibidores de la beta-secretasa
ECSP11011454A (es) 5-alquinil-piridinas
CL2012000393A1 (es) Compuestos octasacaridos n-acilados; composicion farmaceutica; intermediarios; utiles en el tratamiento de enfermedades tales como isquemia, angina de pecho, aterosclerosis, entre otras.
UY33181A (es) Derivados de oxazolopirimidina 2,5-sustituidos.
CU20130065A7 (es) Derivados de indol
UY33877A (es) Derivados de 5-alquinil-piridinas con efecto inhibitorio sobre la actividad de pi3k-alfa